Four of the 10 animals had right eye–induced experimental glaucoma and were monitored longitudinally (
Table 3). Two animals, OHT-71 and OHT-72, showed moderate loss of RNFL thickness, and both animals also had significant reduction of visual field sensitivity as determined with a size III stimulus; OHT-71 had a 5.02-dB reduction in mean sensitivity and OHT-72 a reduction of 2.81 dB. For OHT-73, data were collected until the first time point at which RNFL thickness had decreased below test-retest, and this animal had a reduction in sensitivity as determined with only size I (3.78 dB mean sensitivity) and size II stimulus (2.44 dB mean sensitivity). In contrast, OHT-74, who had a significant reduction in MRW but did not have a reduction in RNFL thickness exceeding repeatability, had no loss of sensitivity with any stimulus size (<1.2-dB loss of mean sensitivity).
The relationship between GCIPL volume and DLS was compared using nonlinear regression. For this analysis, perimetry data (sizes I–V) from the last four time points (approximately 1.5 months of data and with relatively stable structure and functional measures) for all glaucoma eyes and the last time point for the control eyes were used. In all instances, GCIPL structural measures were obtained within ±7 days of the functional data. Of the three models (linear, exponential decay, and segmental), a segmental fit achieved the lowest AIC for the grouped and eccentricity separated data. Furthermore, the slope of the first segment was not significantly different from −1 (
P = 0.81), following that predicted by spatial summation. Subsequently, all GCIPL volume versus DLS data were fit with a segmental function with the slope of the first segment constrained to −1. Furthermore, when separated to the nine eccentricities of the 10-2, the segment intercepts and second line slopes were similar (
P = 0.26,
Table 4,
Fig. 5A), and subsequently, all GCIPL volume data were plotted on a single plot, without including eccentricity. For this combined data set (all four animals), the intersection of the two slopes for the control eyes was determined to be at a GCIPL volume of 2.58 × 10
5 µm
3 (
Fig. 5B), and smaller than that of the glaucomatous eyes, 2.65 × 10
5 µm
3 (
P < 0.01,
Figs. 5C,
5D). This difference represents approximately 1 µm of GCIPL thickness for a size III stimulus, or a 1-µm difference in stimulus diameter for an average GCIPL thickness of 60 µm, which may not be clinically significant. Subsequently, GCIPL data were also transformed based on the histologic correspondence (
Fig. 3C) to determine the relationship between visual thresholds and number of RGCs (
Fig. 6). The segmental fit from this analysis suggests a steeper slope when fewer than 155.6 ± 6.5 RGCs are stimulated.
We subsequently used the segmental fit in
Figures 5B–D to generate a model for predicting visual sensitivity from GCIPL thickness (
Fig. 7). Because GCIPL volume is not a common clinical measure, thickness for this model was estimated for each stimulus size using the lateral magnification of an emmetropic NHP eye. The longitudinal data from the two animals monitored to more severe stages of neuropathy follow that of the predicted structure-function model (
Figs. 7B,
7C).
The data plotted in
Figure 5 show that while the majority of control eye size III stimuli fall on the shallow slope of the segmental fit, with experimental glaucoma, these data shift toward the steeper portion of the function. If Ac is dependent on the number of underlying RGCs, the data in
Figure 5 would suggest a change in the critical area with disease progression. In fact, all three animals with functional loss showed an increase in Ac (
P < 0.01).
Figure 8 illustrates these data for the animal with the greatest (OHT-71) and least (OHT-73) reduction in visual sensitivity. For the more severe subject, Ac was greater than that of a size III stimulus for the majority of eccentricities, while in the less severe subject, although a reduction in sensitivity was noted for size I and II stimuli, Ac was still smaller than that of a size III stimulus.